- Cantel Medical has the legs to reach historical growth levels over the coming periods, backed by a strong Q4 performance.
- Q1 pre-announcements have indicated a stronger than expected sales recovery, and growth cadence has outpaced initial projections.
- Key exposure to infection control consumables, backed by COVID-related demand, should fuel sales growth well into 2021.
- Cost-targeting and liquidity preservation measures since Q3 have fortified the balance sheet, and taken pressure off operating leverage.
- Shares are trading at respectable multiples, and we believe that further upside is likely based on a price target of $85-$87 in the blue-sky scenario.
For further details see:
Cantel Medical: Further Upside Driven By Infection Control Consumables